Pharmaceutical Executive Editors

Pharm Exec profiles its 2023 Emerging Pharma Leaders.

MassBio’s latest Biopharma Funding Report shows Massachusetts biopharma companies raised record-breaking $5.8 billion in VC Funding in 2020.

Prescription opioid Use in the U.S. has declined by 60% from 2011 Peak, according to new report from IQVIA.

AI-powered platform can transform medical expert and opinion leader engagement planning for medical affairs teams.

Pharmaceutical R&D industry report provides insights into what’s behind decline in global NME outputs and reveals implications of decreased projected expenditures.

A technology-enabled solution combining predictive analytics integrated with real-time commercial services for the life sciences sector.

Review platform launches in light of new research which reveals that 93% lack trust in pharma companies.

Filippo Petti is CEO of Celyad Oncology tells Pharm Exec how the pandemic has affected his role as a US-based CEO to a Belgian company.

Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.

W2O, today announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.

IQVIA has announced the launch of OCE Optimizer, which will look to help life sciences companies reach HCPs more effectively.

A recent roundtable of pharmaceutical CEOs, and moderated by Dr. Scott Gottlieb, discussed pressing concerns around the pandemic, including clinical trials, product launches, keeping employees safe and the future of the pharmaceutical industry.

A recent roundtable moderated by Dr. Scott Gottlieb gathered biopharma CEOs to share thoughts and strategies on navigating their companies through the COVID-19 outbreak.

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

In its 12th annual feature, Pharm Exec builds on the revamped approach it introduced last year in spotlighting notable biopharma brands, profiling a new round of products that are making waves in five key areas in healthcare and R&D.